Presentation is loading. Please wait.

Presentation is loading. Please wait.

Progression to micro- or macroalbuminuria.

Published byΑκακιος Αποστολίδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Progression to micro- or macroalbuminuria."— Presentation transcript:

1 Progression to micro- or macroalbuminuria.
Progression to micro- or macroalbuminuria. Kaplan-Meier survival analysis of patients with persistent hyperfiltration at month 6 (persistently hyperfiltering) compared with all other patients who were already normofiltering at inclusion or were hyperfiltering at inclusion and had their hyperfiltration ameliorated at month 6 (others) (log rank: 6.13, P = 0.013). Unadjusted and adjusted HRs are shown in the accompanying table. *Adjustment for albuminuria at baseline. **Adjustments for age, sex, and albuminuria; HbA1c and systolic BP at baseline; smoking habit; known duration of diabetes; participation in the BENEDICT or DEMAND trial; treatment arm; and treatment with an ACE inhibitor yes or no. Mo, month. Piero Ruggenenti et al. Dia Care 2012;35: ©2012 by American Diabetes Association

Download ppt "Progression to micro- or macroalbuminuria."

Similar presentations

All-cause mortality by treatment group

All-cause mortality by treatment group
Change (with 95% CI) in outcomes by duration of type 2 diabetes

Change (with 95% CI) in outcomes by duration of type 2 diabetes
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44:462-472 (DOI:10.1159/000451059)

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )
A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.
A: Kaplan-Meier estimate of time to first LLA

A: Kaplan-Meier estimate of time to first LLA
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:1212-8.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:
Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.

Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.
Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.

Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.
Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.
Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.
Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.

Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.
Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.
Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.
A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (
Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

Similar presentations

Ads by Google